株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

分析ツール:癌治療におけるプロテインキナーゼ阻害剤

Protein Kinase Inhibitors in Oncology: Analytical Tool

発行 BioSeeker Group AB 商品コード 166080
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.67円で換算しております。
Back to Top
分析ツール:癌治療におけるプロテインキナーゼ阻害剤 Protein Kinase Inhibitors in Oncology: Analytical Tool
出版日: 2018年12月05日 ページ情報: 英文
概要

当レポートは、腫瘍治療の領域で事業開発、事業や企業に関する情報収集、臨床開発などに携わっており、注目度が高く、急速に発展しつつあるこの分野で優位を保ちたいと考えている組織の関係者にとって必携のハンドブックです。他に類を見ないこのレポートは、プロテインキナーゼ阻害剤の市販後調査や情報収集で競合他社に対する優位を確保し、的確な意思決定を行って業績を拡大させる一助となるよう考えられています。

当レポートは、プロテインキナーゼ阻害剤の開発状況を絶えず精査し、最新の情報を提供することでこの役割を果たしています。

  • 契約と協力
  • 新たな技術/医薬品 (特許、助成、各種学会での研究発表の要旨などから得られる情報)
  • 資金調達/助成/新規株式公開
  • 出願と承認
  • 臨床試験の最新の動きと結果
  • 新たに始まった臨床試験
  • 世界各地で開催されている腫瘍学関連の12の主要な学会の取材*
  • 四半期レポートと年次レポート

当レポートを活用することで、この分野における日々の動きをほぼ完全に把握することができるほか、製品開発パイプラインの包括的な点検を行ったり、競合企業を評価したりすることができます。また各種の要因を踏まえつつ、腫瘍治療の分野におけるビジネスチャンスや競合企業を特定し、優先順位を設定し、科学的評価を導き出すこともできます。

  • 最新の技術
  • 標的の新規性
  • 最新の研究成果
  • 早期段階および後期段階のパイプライン
  • バイオマーカー/コンパニオン診断の開発
  • 締結された契約や提携
  • 世界の主要ながん関連学会の取材
  • 併用療法の選択肢
  • 臨床試験の結果
  • 適応症の選択と適応拡大の選択肢
  • 既存薬再開発の可能性

当レポートは、現在1,668品目のプロテインキナーゼ阻害剤の開発に取り組んでいる508社以上の企業と提携企業を網羅するもので、そのうちの940品目は322種類の標的のがんに対応する製品として積極的に開発が進められています。本調査レポートの分析ツールで得られるデータや分析は、クライアントの側で保存することが可能であり、データ/グラフ/表をExcel/PDFなどさまざまな形式のファイルにエクスポートし、クライアントが独自に集めた情報と組み合わせることもできます。

システムの要求仕様

  • ブラウザアプリケーション (Internet Explorer、FireFox、Chrome、Safariに対応)
  • インターネットアクセス
目次
Product Code: BSG21823

Kinase-targeted cancer therapies became really big with imatinib (Gleevec), a landmark drug that has vastly improved the outcomes of patients with chronic myelogenous leukemia. With the human genome encoding 538 protein kinases and many of these kinases being associated with human cancer initiation and progression, this field carries a lot of promise for more treatment successes in the future.

Protein Kinase Inhibitors in Oncology: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your PKI drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.

Keeping you "In the know"

Simply put, our mission is to fuel your knowledge of oncology, to make you the first to know about very early technologies and startups, emerging clinical trial results, drug approvals and the ever-changing competitive landscape. Protein Kinase Inhibitors in Oncology: Analytical Tool achieves this by continuously scanning development in PKI and reporting:

  • Deals & Collaborations
  • New technologies/drugs (emerging from patents, grants, abstracts (see Conference Coverage) etc.)
  • Funding/Grants/IPOs
  • Filings & Approvals
  • Latest Clinical Trial Development & Results
  • Newly launched clinical trials
  • Conference Coverage of the world's twelve leading meetings in oncology*
  • Quarterly & Annual Reporting

This puts you in control of most, if not all, day-to-day developments in your field while also benefiting from one of the most comprehensive commercial pipeline review & competitive assessment tools available on the market today! Identify, prioritize, and lead scientific assessment of oncology opportunities and competition by multiple factors such as:

  • Emerging Technologies
  • Target Novelty
  • Recent Funding
  • Early & Late Stage Pipeline
  • Biomarker/Companion Diagnostic Development (featured below)
  • Entered Deals & Alliances
  • Conference surveillance of world leading cancer meetings (featured below)
  • Combination Therapy Choices (featured below)
  • Outcome of Clinical Trials
  • Indication Selection & Expansion Choices
  • Drug Repositioning Opportunities

For 20 years we have supported better decision making across the oncology drug development industry. Your Protein Kinase Inhibitors in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computer's desktop into a high capacity workbench within your area of choice. Even before launching this tool you have already eliminated the hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf.

Your Protein Kinase Inhibitors in Oncology: Analytical Tool covers more than 508 companies plus partners who are today developing 1668 PKI drugs where of 940 are in active development in cancer across 322 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.

Let our expertise work for you

With a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.

Your key to access development at the world-leading cancer meetings

The Protein Kinase Inhibitors in Oncology: Analytical Tool is continuously updated according to twelve of the world's most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia). If you are not able to attend any of the conference(s) in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about.

Run combination therapy analysis like no other

The Protein Kinase Inhibitors in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.

Unparalleled biomarker surveillance

We also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.

Support and inspiration at your finger-tips

You also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.

A tool to grow with and keep you informed

Unlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc. You can choose to renew your access to these updates and support on a yearly basis or go over to our industry leading full service platform covering all oncology drug development, 1stOncology.

System Requirements

  • Browser Application (Supports: Internet Explorer, FireFox, Chrome and Safari))
  • Internet access
Back to Top